<p>Metabolic disorders, including obesity, type 2 diabetes mellitus, dyslipidemia, and non-alcoholic fatty liver disease, represent a growing global health challenge driven by lifestyle, genetic, and environmental factors. Emerging evidence highlights the critical role of gut microbiota in metabolic regulation, with dysbiosis contributing to systemic inflammation, insulin resistance, and altered lipid metabolism. Probiotics have shown promise in modulating gut microbiota composition and function. Through mechanisms such as enhancing gut barrier integrity, producing beneficial metabolites (e.g., SCFAs), and modulating immune responses, specific probiotic strains can ameliorate metabolic dysfunction. This review synthesizes current findings on the role of probiotics in managing metabolic disorders, focusing on preclinical and clinical evidence, strain-specific effects, and mechanistic pathways. The potential of next-generation probiotics and synbiotic formulations is also discussed. While clinical outcomes are promising, variability in individual responses and lack of standardized protocols highlight the need for precision probiotic therapies, warranting further research and clinical integration.</p>